XAF1 Antibody [C23J4] | Primary Antibodies

Application: Reactivity: Human

Lane 1: Hela, Lane 2: Hela (IFN-α, 10 ng/ml, 16 h)

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
32 kDa, 38 kDa

Datasheet & SDS

Biological Description

Specificity
XAF1 Antibody [C23J4] detects endogenous levels of total XAF1 protein.

Clone
C23J4

Synonym(s)
XIAP-associated factor 1; XAF1

Background
X‑linked inhibitor of apoptosis‑associated factor 1 (XAF1) is a zinc finger–containing protein that functions as a pro‑apoptotic tumor suppressor by antagonizing the anti‑caspase activity of XIAP and modulating multiple stress‑signaling pathways. XAF1 contains several C2‑H2 zinc finger motifs that mediate protein–protein interactions, including direct binding to XIAP, p53, and components of the HIPK2–ZNF313 axis, allowing it to influence the stability and activity of these regulators rather than simply acting as a neutral adaptor. XAF1 is transcriptionally induced via STAT‑ and IRF‑1‑dependent circuits and functions as a feedback amplifier of interferon signaling, enhancing stress‑induced apoptosis and cellular sensitivity to exogenous death signals, while in p53‑proficient cells XAF1 forms a positive feedback loop with p53 by competing with the E3 ubiquitin ligase MDM2 for binding to p53, thereby stabilizing p53 and promoting HIPK2‑mediated p53 Ser46 phosphorylation and ZNF313‑dependent ubiquitination of p21, which collectively bias p53 outcomes toward apoptosis rather than cell‑cycle arrest. XAF1 engages non‑caspase‑dependent outputs, including autophagy induction via modulation of the Akt–p70S6K pathway and upregulation of Beclin‑1, and recent evidence indicates that XAF1 can be actively secreted from stressed tumor cells through an endolysosomal route to enhance T‑cell‑mediated tumor surveillance, linking intrinsic ER‑stress and DNA‑damage signaling to adaptive immune control. XAF1 expression is frequently suppressed by promoter hypermethylation or p53‑linked repression, and low XAF1 levels correlate with advanced stage, poor differentiation, and worse prognosis in multiple epithelial malignancies, whereas its restoration impairs tumor growth and sensitizes cells to cytotoxic agents.

Background

X‑linked inhibitor of apoptosis‑associated factor 1 (XAF1) is a zinc finger–containing protein that functions as a pro‑apoptotic tumor suppressor by antagonizing the anti‑caspase activity of XIAP and modulating multiple stress‑signaling pathways. XAF1 contains several C2‑H2 zinc finger motifs that mediate protein–protein interactions, including direct binding to XIAP, p53, and components of the HIPK2–ZNF313 axis, allowing it to influence the stability and activity of these regulators rather than simply acting as a neutral adaptor. XAF1 is transcriptionally induced via STAT‑ and IRF‑1‑dependent circuits and functions as a feedback amplifier of interferon signaling, enhancing stress‑induced apoptosis and cellular sensitivity to exogenous death signals, while in p53‑proficient cells XAF1 forms a positive feedback loop with p53 by competing with the E3 ubiquitin ligase MDM2 for binding to p53, thereby stabilizing p53 and promoting HIPK2‑mediated p53 Ser46 phosphorylation and ZNF313‑dependent ubiquitination of p21, which collectively bias p53 outcomes toward apoptosis rather than cell‑cycle arrest. XAF1 engages non‑caspase‑dependent outputs, including autophagy induction via modulation of the Akt–p70S6K pathway and upregulation of Beclin‑1, and recent evidence indicates that XAF1 can be actively secreted from stressed tumor cells through an endolysosomal route to enhance T‑cell‑mediated tumor surveillance, linking intrinsic ER‑stress and DNA‑damage signaling to adaptive immune control. XAF1 expression is frequently suppressed by promoter hypermethylation or p53‑linked repression, and low XAF1 levels correlate with advanced stage, poor differentiation, and worse prognosis in multiple epithelial malignancies, whereas its restoration impairs tumor growth and sensitizes cells to cytotoxic agents.

References
https://pubmed.ncbi.nlm.nih.gov/25313037/ https://pubmed.ncbi.nlm.nih.gov/30042418/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%